Intellia is committed to working closely with healthcare professionals to improve the standard of care for patients by harnessing the power of CRISPR/Cas9-based genome editing. We are developing potential single-adminstration therapies for people living with severe and life-threatening conditions, including cancer and genetic disorders.

How We Are Developing CRISPR/Cas9-Based Treatments

At Intellia, we utilize a modular genome editing platform to create a diverse pipeline, including programs that apply genome editing in vivo, where the CRISPR/Cas9 components are delivered as the therapy, and ex vivo, where we use our CRISPR/Cas9 technology as a tool to create engineered, cell-based therapies.

Access to Our Investigational Medicines

Intellia is committed to solving the complex challenges of making CRISPR/Cas9-based medicines a reality for patients suffering with severe and life-threatening genetic diseases.

Under certain circumstances, a person suffering a serious or life-threatening disease may ask to use an experimental treatment outside a clinical trial, before its safety and efficacy have been fully evaluated, and before the regulatory authorities have approved it. Intellia appreciates the intent of expanded access programs but, at this time, we can best advance the development of these potential promising products by enrolling patients in clinical trials.

Click here to read our full expanded access policy.

If you have questions regarding information on our programs, check out our pipeline or contact [email protected].